

CHRONICKÁ LYMFOCYTÁRNÍ LEUKEMIE A MALIGNÍ LYMFOMY

CHRONICKÁ LYMFOCYTÁRNÍ LEUKEMIE A MALIGNÍ LYMFOMY NA ASH® 2019

| | |
|---|---------|
| LUKÁŠ SMOLEJ | str. 5 |
| NIVOLUMAB AND AVD FOR EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (NIVAHL) | str. 9 |
| THE EVALUATION AND TREATMENT (TX) OF BURKITT LYMPHOMA (BL) IN THE MODERN ERA: REAL WORLD (RW) OUTCOMES AND PROGNOSTICATION ACROSS 26 US CANCER CENTERS (CC) | str. 11 |
| PROSPECTIVE, MULTICENTRIC PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF METHOTREXATE OR CYCLOPHOSPHAMIDE IN LARGE GRANULAR LYMPHOCYTIC LEUKEMIA: A FRENCH NATIONAL STUDY. REPORT ON THE INTERIM ANALYSIS | str. 14 |
| A MULTICENTRE, RETROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE CLINICAL OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) TREATED WITH IDELALISIB AND RITUXIMAB IN THE UK (RETRO-IDEL) – A COHORT OF 110 PATIENTS | str. 16 |
| FRONT-LINE TREATMENT WITH OBINUTUZUMAB ± CHLORAMBUCIL FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN REAL-WORLD CLINICAL PRACTICE: RESULTS OF A MULTINATIONAL, MULTICENTER STUDY BY ERIC AND ICLLSG | str. 18 |
| PEGASPARGASE CAN SAFELY BE ADMINISTERED IN ADULTS AGE 40 AND OLDER WITH ACUTE LYMPHOBLASTIC LEUKEMIA | str. 20 |

IMUNITNÍ TROMBOCYTOPENIE

IMUNITNÍ TROMBOCYTOPENIE – ZAJÍMAVOSTI Z ASH®

| | |
|---|---------|
| LIBOR ČERVINEK | str. 23 |
| PHASE I/II, OPEN-LABEL, ADAPTIVE STUDY OF ORAL BRUTON TYROSINE KINASE INHIBITOR PRN1008 IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY OR SECONDARY IMMUNE THROMBOCYTOPENIA | str. 27 |
| PHASE II STUDY OF EFGARTIGIMOD, A NOVEL FCRN ANTAGONIST, IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA | str. 29 |
| ROZANOLIXIZUMAB, AN ANTI-FCRN ANTIBODY: FINAL RESULTS FROM A PHASE II, MULTIPLE-DOSE STUDY IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA | str. 31 |

AKUTNÍ MYELOIDNÍ LEUKEMIE

AKUTNÍ MYELOIDNÍ LEUKEMIE

| | |
|---|---------|
| TOMÁŠ STOPKA | str. 33 |
| PATTERNS OF CARE AND CLINICAL OUTCOMES WITH 7 + 3 INDUCTION CHEMOTHERAPY FOR PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN THE UNITED STATES (US): A LARGE POPULATION-BASED STUDY | str. 40 |

RESPONSE TO SORAFENIB IN FLT3/ITD AML IS DEPENDENT ON CO-OCCURRING MUTATIONAL PROFILE str. 42

MAINTENANCE DECITABINE (DAC) IMPROVES DISEASE-FREE (DFS) AND OVERALL SURVIVAL (OS) AFTER INTENSIVE THERAPY FOR ACUTE MYELOID LEUKEMIA (AML) IN OLDER ADULTS, PARTICULARLY IN FLT3-ITD-NEGATIVE PATIENTS: ECOG-ACRIN (E-A) E2906 RANDOMIZED STUDY str. 45

CHRONICKÁ MYELOIDNÍ LEUKEMIE

CHRONICKÁ MYELOCYTOVÁ LEUKÉMIA – NOVINKY Z VÝROČNEJ KONFERENCIE ASH® 2019
JURAJ SOKOL str. 47

PREGNANCY MANAGEMENT IN CML PATIENTS: TO TREAT OR NOT TO TREAT? REPORT OF 224 OUTCOMES OF THE EUROPEAN LEUKEMIA NET (ELN) DATABASE str. 52

RNA SPLICING DEFECTS IN CANCER-LINKED GENES INDICATE MUTATION OR FOCAL GENE DELETION AND ARE ASSOCIATED WITH TKI RESISTANCE IN CML str. 54

THE IMPACT OF TREATMENT RECOMMENDATION BY LEUKEMIA ARTIFICIAL INTELLIGENCE PROGRAM (LEAP) ON SURVIVAL IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) str. 57

MYELOYDYSPLASTICKÝ SYNDROM

MYELOYDYSPLASTICKÝ SYNDROM – CO PŘINESL ASH® 2019
ANNA JONÁŠOVÁ str. 59

THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB (5F9) IN COMBINATION WITH AZACITIDINE IS EFFECTIVE IN MDS AND AML PATIENTS: ONGOING PHASE IB RESULTS str. 64

GENOMIC CONTEXT AND TP53 ALLELE FREQUENCY DEFINE PROGNOSTIC SUBGROUPS AND RESPONSE OUTCOMES IN TP53 MUTATED MYELOYDYSPLASTIC SYNDROMES str. 66

LONG TERM EFFECTS OF ELTROMBOPAG TREATMENT VERSUS PLACEBO FOR LOW-RISK MYELOYDYSPLASTIC SYNDROMES WITH THROMBOCYTOPENIA (EQOL-MDS): INTERIM RESULTS OF A SINGLE-BLIND, RANDOMISED, CONTROLLED, PHASE II SUPERIORITY TRIAL str. 68

MYELOPROLIFERATIVNÍ NEOPLAZIE

MYELOPROLIFERATIVNÍ NEOPLAZIE – ZAJÍMAVÁ SDĚLENÍ Z ASH®
LIBOR ČERVINEK str. 71

THROMBOEMBOLIC RISK REDUCTION AND HIGH RATE OF COMPLETE MOLECULAR RESPONSE WITH LONG-TERM USE OF ROPEGINTERFERON ALPHA-2B IN POLYCYTHEMIA VERA: RESULTS FROM A RANDOMIZED CONTROLLED STUDY str. 75

RESULTS OF PAC203: A RANDOMIZED PHASE II DOSE-FINDING STUDY AND DETERMINATION OF THE RECOMMENDED DOSE OF PACRITINIB str. 77

FEDRATINIB INDUCES SPLEEN RESPONSES AND REDUCES SYMPTOM BURDEN IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN)-ASSOCIATED MYELOFIBROSIS (MF) AND LOW PLATELET COUNTS, WHO WERE EITHER RUXOLITINIB-NAÏVE OR WERE PREVIOUSLY TREATED WITH RUXOLITINIB str. 79